Clinical Trials Logo

Active Dermatomyositis clinical trials

View clinical trials related to Active Dermatomyositis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02029274 Terminated - Clinical trials for Active Dermatomyositis

Safety and Efficacy of BAF312 in Dermatomyositis

Start date: August 25, 2013
Phase: Phase 2
Study type: Interventional

This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. The study was composed of 2 periods: a double-blind period 1 with BAF312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose Period 2 in which BAF312 was administered at the dose of 2 mg daily .